Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://fractyl.comNext earnings report:
30 August 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 15 min agoDividend
Analysts recommendations
Institutional Ownership
GUTS Latest News
BURLINGTON, Mass., June 25, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, and Dr. Timothy Kieffer, CSO of Fractyl Health, will participate in a virtual fireside chat at the upcoming Piper Sandler 2nd Annual Virtual Obesity Day on Wednesday, June 26, 2024 at 9:30 a.m.
Company will accelerate Revita® weight maintenance clinical study REMAIN-1; open label data from REVEAL-1 cohort expected in Q4 2024 and mid-point data analysis for REMAIN-1 anticipated in Q2 2025 Company expands Revita type 2 diabetes clinical study REVITALIZE-1, expanding eligibility; increases potential U.S. treatment population for Revita by over 6x (from ~4 to ~25 million patients) Company presented preclinical data showing greater, more durable weight loss for its GLP-1 pancreatic gene therapy Rejuva® vs. semaglutide in one of eight President Select Abstracts at the American Diabetes Association's 84 th Scientific Sessions BURLINGTON, Mass.
Fractyl Health, Inc. (NASDAQ: GUTS) Q1 2024 Earnings Conference Call on May 13, 2024 at 4:30 PM ET with Company Participants Stephen Jasper from Gilmartin Group, Harith Rajagopalan, Lisa Davidson, Timothy Kieffer, and Adrian Kimber. Conference Call Participants include Michael DiFiore from Evercore ISI and Michael Ulz from Morgan Stanley. The Operator welcomes everyone to Fractyl Health's First Quarter Financial Results and Business Updates Call, which is being recorded.
Volatile stocks are essential for short-term traders, as they offer the potential to profit in both upward and downward movements. Identifying the most volatile stocks is key for day traders and swing traders to capitalize on quick cash opportunities.
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million.
Obesity and diabetes drug developer Fractyl Health on Thursday priced its U.S. initial public offering (IPO) below an indicated range to raise $110 million.
Thus far, 2024 has been a mixed year for initial public offerings (IPOs). Various IPOs in 2023 performed well, but many underperformed expectations.
Therapy developer Fractyl Health said on Monday it was aiming for a market valuation of up to $762 million in its U.S. initial public offering (IPO).
Fractyl Health, Inc. has filed for a $100 million IPO to raise funds for its treatments for Type 2 Diabetes and obesity, although the final figure may differ. The company's lead procedural approach, Revita DMR System, is already approved in Europe. The global market for Type 2 diabetes drug treatments is expected to reach $61.6 billion by 2030.
What type of business is Fractyl Health Common Stock?
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
What sector is Fractyl Health Common Stock in?
Fractyl Health Common Stock is in the Healthcare sector
What industry is Fractyl Health Common Stock in?
Fractyl Health Common Stock is in the Biotechnology industry
What country is Fractyl Health Common Stock from?
Fractyl Health Common Stock is headquartered in United States
What is Fractyl Health Common Stock website?
https://fractyl.com
Is Fractyl Health Common Stock in the S&P 500?
No, Fractyl Health Common Stock is not included in the S&P 500 index
Is Fractyl Health Common Stock in the NASDAQ 100?
No, Fractyl Health Common Stock is not included in the NASDAQ 100 index
Is Fractyl Health Common Stock in the Dow Jones?
No, Fractyl Health Common Stock is not included in the Dow Jones index
When does Fractyl Health Common Stock report earnings?
The next expected earnings date for Fractyl Health Common Stock is 30 August 2024